Loading…
Loading…
See exactly how PBE's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PBE and 80,000+ other tickers.
The Invesco Biotechnology & Genome ETF (PBE) seeks to replicate the performance of the Dynamic Biotech & Genome Intellidex Index. This fund typically allocates a minimum of 90% of its total assets to the securities comprising the underlying index. The Index is constructed to achieve capital appreciation by thoroughly evaluating companies based on several investment criteria, including their price momentum, earnings growth, overall quality, management decisions, and valuation. It consists of 30 U.S.-based companies within the biotechnology and genome sectors. These companies are primarily…
PBE offers a higher dividend yield and has delivered stronger one-year total returns. RSPH offers a more affordable expense ratio and a significantly lower historical drawdown.
iShares U.S. Healthcare ETF offers a more diversified portfolio and lower expense ratio than Invesco Biotechnology & Genome ETF. Invesco Biotechnology & Genome ETF delivered a higher 1-year total return but has experienced significantly larger historical drawdowns.
IHE delivered 53.2% returns over one year with lower volatility and a 0.37% expense ratio, while PBE's quantitative biotech strategy carries higher risk.
Designed to provide broad exposure to the Health Care ETFs category of the market, the Invesco Biotechnology & Genome ETF (PBE) is a smart beta exchange traded fund launched on 06/23/2005.
VanEck targets established pharma giants with lower costs and volatility, while Invesco pursues high-growth biotech companies. One delivered stronger returns; the other weathered downturns better.